Lead Product(s) : Milnacipran HCl
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2014
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of F2695 on Functional Recovery After Ischemic Stroke
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2012
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2011
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2010
Lead Product(s) : Milnacipran HCl
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
